Ardigen's news feed
Share news in:

Immudex and Ardigen announce partnership

Immudex and Ardigen announce partnership on Immune Profiling multi-omics data analysis services

Immudex and Ardigen are pleased to announce their strategic partnership, combining expertise to offer comprehensive Immune Profiling Multi-Omics Data Analysis Services tailored for the pharmaceutical industry. This collaboration focuses on the single-cell multi-omics analysis of antigen-specific immune cells, enhancing research capabilities in precision medicine and drug development.

Immudex, renowned for its DNA barcoded dCODE® reagents, provides unparalleled solutions for single-cell multi-omics analysis of antigen-specific B and T cells. The dCODE reagents link BCR/TCR sequences to the cognate antigen/peptide-MHC complex, allowing for an integrated analysis of gene expression and surface protein expression. This comprehensive approach offers an in-depth understanding of the adaptive immune response at single-cell resolution.

By transforming multi-omics datasets into actionable scientific insights, Ardigen increases the probability of success in precision medicine and drug development. Their robust data analysis platform ensures precise data pre-processing, QC, and normalization, essential for successful analysis and interpretation.

Through this partnership, Immudex and Ardigen provide Immune Profiling Multi-Omics Data Analysis services to various clients. This enables detailed analysis of TCR and BCR clonotypes and a holistic characterization of individual immune cells, linking antigen specificity, gene expression, and surface markers. The service offers expert advice on experimental design and guarantees comprehensive analysis of datasets.

Leadership Perspectives

Henrik Pfundheller, CCO of Immudex, comments:

“Immune profiling using single-cell multi-omics creates a wealth of data. Analyzing and integrating immunology and genomics datasets can be challenging, but it is vitally important for the development of cancer vaccines and immunotherapies. We are pleased to partner with Ardigen to enable customers to outsource the analysis of their dCODE® datasets to a reliable service provider.”

Michał Warchoł, CTO of Ardigen, comments:

“The partnership with Immudex enables clients to receive expert advice when designing their immune profiling experiments and be assured that their datasets will be comprehensively analyzed using our robust data analysis platform. Proper data preprocessing, QC and normalization are all crucial to be able to successfully analyze and interpret the data”

Comprehensive solutions for Immune Profiling

dCODE® Reagents from Immudex

dCODE® reagents are available for analyzing antigen-specific CD8+ T cells, CD4+ T cells, B cells, and non-conventional T cells (MAIT cells and iNKT cells). Based on Dextramer® technology, the high-avidity dCODE® reagents ensure analysis of even rare or low-affinity immune cells. Compatible with BD Rhapsody™ and 10x Chromium platforms, these reagents support applications from high-throughput screening to monitoring selected targeted antigen specificities.

Advanced services from Ardigen

Ardigen offers a broad range of services, including small molecule morphological profiling, identification of therapeutic targets, immunotherapy, and microbiome analysis. Their partnership with top scientific institutes and technology providers underscores their commitment to innovation and excellence in drug discovery.

For more information on the partnership and services, explore the following resources:

Immudex and Ardigen are excited to embark on this partnership, setting a new standard in Immune Profiling Multi-Omics Data Analysis and accelerating advancements in precision medicine.

About Immudex

Immudex ApS is a pioneering life science company specializing in precision cellular immune monitoring. With headquarters in Copenhagen, Denmark, and operations in Fairfax, Virginia, Immudex’s Dextramer® technology is renowned for detecting antigen-specific immune cells. Their product portfolio supports diverse applications in immuno-oncology, transplantation, autoimmune, and infectious diseases. Discover more at


Ardigen at BioIT 2024
Go up